Icosagen Cell Factory and Swedish Orphan Biovitrum prologned a contract
Icosagen Cell Factory OÜ and Swedish Orphan Biovitrum AB (SOBI) prolonged an agreement pursuant to which a technology licence to SOBI was granted to evaluate the QMCF Technology with the option to proceed with a license to use the Technology for research activities.
QMCF Technology is a simple and efficient method for production of any kind of proteins for research use or for development of biological therapeutics. The uniqueness of the technology bases on the use of a proprietary combination of regulatory elements in mammalian QMCF cells that ensure stable replication and maintenance of the QMCF plasmids. The extended episomal maintenance (up to 2 months) allows high productivities and fast cell bank generation of the transfected cells. In addition, the technology is applicable to development cell-based assays for drug target screening. The Technology has been granted by European and US Patent.
About Icosagen Cell Factory
Icosagen Cell Factory OÜ was established in 2005. The company is dedicated to the development of the portfolio of QMCF Technology-based applications. The R&D work during 2005-2008 was performed in collaboration with Tartu University and financed by Enterprise Estonia.
About Swedish Orphan Biovitrum (Sobi)
Sobi is a Swedish based niche specialty pharmaceutical company with an international market presence. The company is focused on providing and developing specialist pharmaceuticals for rare disease patients with high medical needs. The portfolio consists of about 60 marketed products and an emerging late stage clinical development pipe-line. Our focus areas are: hemophilia, inflammation/autoimmune diseases, fat malabsorption, cancer supportive care and inherited metabolic disorders.
Icosagen Cell Factory OÜ
Marit Jaaska, Business Development Manager
Phone: +372 737 7070